TIXiMED Initiates Phase 1b Multiple Ascending Dose Study of TIX100

TIXiMED Initiates Phase 1b Multiple Ascending Dose Study of TIX100

Phase 1b Multiple Ascending Dose (MAD) Study to Evaluate Safety, Tolerability, and Pharmacokinetics of an Investigational Oral Disease-Modifying Type 1 Diabetes Therapy

Study Builds on Phase 1a Single Ascending Dose Results Demonstrating Safety, Tolerability, and First Metabolic Signal of TIX100 in Humans

TIXiMED, Inc. (www.TIXiMED.com), a clinical-stage pharmaceutical company developing a novel disease-modifying oral therapy for type 1 diabetes (T1D), today announced the initiation of the Phase 1b Multiple Ascending Dose (MAD) study of TIX100 (NCT07675590), an investigational oral inhibitor of thioredoxin-interacting protein (TXNIP).

The TIX100 MAD study is a double-blind, randomized, placebo-controlled trial evaluating the safety, tolerability, and pharmacokinetics of orally administered TIX100. The study will enroll 18 healthy subjects across three ascending dose cohorts at a single US center, with each cohort receiving TIX100 or placebo twice daily for 28 days, followed by a seven-day follow-up.